Published in Front Biosci on January 01, 2007
Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer (2009) 1.31
Aryl hydrocarbon receptor and lung cancer. Anticancer Res (2013) 0.99
Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab (2010) 0.98
Representative Sinusoids for Hepatic Four-Scale Pharmacokinetics Simulations. PLoS One (2015) 0.80
Analysis of the AHR gene proximal promoter GGGGC-repeat polymorphism in lung, breast, and colon cancer. Toxicol Appl Pharmacol (2014) 0.77
Harmine and harmaline downregulate TCDD-induced Cyp1a1 in the livers and lungs of C57BL/6 mice. Biomed Res Int (2012) 0.76
Expression Profile of Genes Related to Drug Metabolism in Human Brain Tumors. PLoS One (2015) 0.75
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet (2003) 4.01
An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A (2005) 2.18
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer (2003) 2.01
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood (2003) 1.99
Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev (2003) 1.76
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol (2005) 1.75
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol (2011) 1.71
Bisphenol A levels in human urine. Environ Health Perspect (2003) 1.70
Biological monitoring of bisphenol a in a Korean population. Arch Environ Contam Toxicol (2003) 1.60
Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest (2002) 1.59
Metabolism of vitamin D3 by cytochromes P450. Front Biosci (2005) 1.52
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res (2009) 1.52
Survival and prognostic factors of surgically resected T4 non-small cell lung cancer. Ann Thorac Surg (2003) 1.49
Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer. Ann Thorac Surg (2013) 1.44
Manganese superoxide dismutase and aldehyde dehydrogenase deficiency increase mitochondrial oxidative stress and aggravate age-dependent vascular dysfunction. Cardiovasc Res (2008) 1.43
National survey of endoscopic thymectomy: survey report from the Japanese Association for Research on the Thymus. Gen Thorac Cardiovasc Surg (2009) 1.39
Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg (2010) 1.39
A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res (2003) 1.36
Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer (2005) 1.32
Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol (2008) 1.32
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res (2010) 1.31
Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol (2005) 1.29
Thoracoscopic treatment of Bochdalek hernia in the adult: report of a case. Ann Thorac Cardiovasc Surg (2002) 1.29
Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci (2007) 1.28
Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res (2011) 1.28
Transcriptional activation of human CYP17 in H295R adrenocortical cells depends on complex formation among p54(nrb)/NonO, protein-associated splicing factor, and SF-1, a complex that also participates in repression of transcription. Endocrinology (2002) 1.25
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer (2009) 1.23
Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling. Cancer Res (2013) 1.23
Urinary concentrations of bisphenol A in relation to biomarkers of sensitivity and effect and endocrine-related health effects. Environ Mol Mutagen (2006) 1.20
Successful extirpation of thoracic pleural lipoma by single-port thoracoscopic surgery. Asian J Surg (2011) 1.18
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer (2008) 1.18
Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res (2003) 1.16
Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci (2011) 1.16
Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer. J Clin Oncol (2002) 1.15
Matrix metalloproteinase 12 accelerates the initiation of atherosclerosis and stimulates the progression of fatty streaks to fibrous plaques in transgenic rabbits. Am J Pathol (2008) 1.14
Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer (2009) 1.13
Three-dimensional structure of steroid 21-hydroxylase (cytochrome P450 21A2) with two substrates reveals locations of disease-associated variants. J Biol Chem (2012) 1.13
The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther (2004) 1.12
Purification and characterization of bovine steroid 21-hydroxylase (P450c21) efficiently expressed in Escherichia coli. Biochem Biophys Res Commun (2006) 1.11
Tracheobronchopathia osteochondroplastica occurring in a subsegmental bronchus and causing obstructive pneumonia. Ann Thorac Surg (2005) 1.11
Human mitochondrial transcription factor A binds preferentially to oxidatively damaged DNA. Biochem Biophys Res Commun (2002) 1.10
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet (2011) 1.10
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol (2009) 1.10
Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res (2004) 1.09
Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol (2003) 1.09
ALDH-2 deficiency increases cardiovascular oxidative stress--evidence for indirect antioxidative properties. Biochem Biophys Res Commun (2007) 1.09
p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem (2002) 1.09
Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol (2010) 1.08
Aldehyde dehydrogenase 2 gene targeting mouse lacking enzyme activity shows high acetaldehyde level in blood, brain, and liver after ethanol gavages. Alcohol Clin Exp Res (2005) 1.08
Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer (2010) 1.08
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer (2013) 1.08
Formation of acetaldehyde-derived DNA adducts due to alcohol exposure. Chem Biol Interact (2010) 1.07
Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice. Hepatology (2014) 1.06
Aldehyde dehydrogenase 2 knockout accentuates ethanol-induced cardiac depression: role of protein phosphatases. J Mol Cell Cardiol (2010) 1.06
Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer. Lung Cancer (2004) 1.05
Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and Survival. Ann Surg (2002) 1.05
Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer (2011) 1.04
Immunohistochemical alpha- and beta-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma. Pathol Res Pract (2006) 1.04
Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer (2002) 1.04
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol (2003) 1.03
The expression of Ki-67, but not proliferating cell nuclear antigen, predicts poor disease free survival in patients with adenocarcinoma of the lung. Anticancer Res (2011) 1.03
Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci (2007) 1.01
Total vertebrectomy for non-small cell lung cancer. Case Rep Oncol (2012) 1.01
Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol (2005) 1.01
Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer (2004) 1.01
Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. J Clin Oncol (2004) 1.00
Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents. J Biol Chem (2002) 1.00
First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component. J Thorac Oncol (2012) 1.00
Effects of aldehyde dehydrogenase-2 genetic polymorphisms on metabolism of structurally different aldehydes in human liver. Drug Metab Dispos (2002) 1.00
Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res (2003) 0.99
H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factors. J Leukoc Biol (2002) 0.99
EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci (Landmark Ed) (2010) 0.99
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol (2007) 0.98
p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y. J Biol Chem (2002) 0.98
Visceral pleural involvement in nonsmall cell lung cancer: prognostic significance. Ann Thorac Surg (2004) 0.98
The ferrous-oxy complex of human aromatase. Biochem Biophys Res Commun (2008) 0.98
Time trends of surgical outcome in patients with non-small cell lung cancer. J Thorac Oncol (2010) 0.98